Nanobiotix S.A.
NANO.PA · PAR
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.06 | 0.09 | 0.16 |
| FCF Yield | -9.86% | -2.68% | 1.90% | -11.01% |
| EV / EBITDA | -3.24 | -9.40 | -46.05 | -7.75 |
| Quality | ||||
| ROIC | -333.42% | -67.71% | -2.90% | -11,792.86% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 77.53% |
| Cash Conversion Ratio | 3.23 | 0.30 | 0.27 | -0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 707.66% | 492.94% | 217.86% | 126.07% |
| Free Cash Flow Growth | -122.51% | -231.94% | 126.78% | 11.19% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.74 | 5.00 | -1.29 |
| Interest Coverage | -5.53 | -6.13 | -0.34 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -36.76 | 30.24 | 236.87 | -1,040.84 |